Theratechnologies Inc (TSE:TH) had its target price raised by National Bank Financial from C$9.25 to C$9.75 in a research report sent to investors on Friday, October 6th. They currently have an outperform rating on the stock. National Bank Financial also issued estimates for Theratechnologies’ Q3 2017 earnings at ($0.02) EPS, FY2017 earnings at ($0.16) EPS and FY2018 earnings at $0.35 EPS.
Separately, Scotiabank lowered their price objective on Theratechnologies from C$9.50 to C$9.25 and set an outperform rating for the company in a research report on Friday, September 29th.
Theratechnologies (TSE:TH) opened at 7.84 on Friday. The stock’s market cap is $583.41 million. Theratechnologies has a one year low of $2.61 and a one year high of $8.72. The stock has a 50 day moving average price of $7.59 and a 200-day moving average price of $7.31.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with our FREE daily email newsletter.